Research Ready™ Program Expands and Diversifies Clinical Trial Patient Populations


Company News Release

Austin, Texas, May 15, 2018 (BUSINESS WIRE) - Elligo Health Research, which improves clinical trial access by engaging the 97 percent of physicians currently not offering clinical research to their patients, has launched a Research Ready™ program for physician practices interested in becoming a study site. Through the program, health care providers are able to offer clinical research studies as a care option to their patients. As a result, patient participation and retention rates increase, contributing to a more diverse population of patients and subsequently enabling clinical research organizations (CROs) and sponsors to get their studies up and running faster.    The Research Ready™ program is part of Elligo’s Goes Direct™ approach, which provides a larger patient pool, more randomizations and better retention by making clinical research studies accessible to physicians and their patients. Through the program, physician practices are evaluated on a number of study-related components and are provided the technology, the infrastructure and a clinical coordinator to perform trials.   “We know patient diversification is important for our trial sponsors and CROs,” said John Potthoff, Ph.D., CEO of Elligo. “We make it easier for more patients to participate in trials through their own trusted physician. And, not only are our sites benefiting from the infrastructure support, but our sponsors and CROs are getting quality study data from community practice researchers.”    Every research site conducting research with Elligo has received the Research Ready™ designation. Currently, Elligo has more than 200 physician partners - with specialization in women’s health, gastroenterology, urology and pain management indications.      About Elligo Health ResearchElligo Health Research offers the only platform that brings clinical research to physician practices, accelerating the development of new pharmaceutical, biotechnology and medical device products and therapies. Our Goes Direct™ approach uses state-of-the-art elliGO DIRECT™ technology to compliantly leverage current electronic health record data and applies a proprietary, prescreening process to match protocol-eligible patients for participation in clinical studies. It is our mission to support health care providers by providing personnel, procedures, technology and infrastructure for clinical research, enabling patients to participate in research while remaining under the care of their own trusted physician. Learn more at   CONTACT: Lea Studer  SCORR Marketing 402.366.1752

Related Videos
Greg Ball, Founder, ASAP Process Consulting image credit screen shot from video
Janice Chang, CEO, TransCelerate BioPharma @ video screenshot.
Related Content
© 2024 MJH Life Sciences

All rights reserved.